Skip to main content
Article thumbnail
Location of Repository

Brain lesion volume and capacity for consent in stroke trials: potential regulatory barriers to the use of surrogate markers

By K.A. Dani, M.T. McCormick and K.W. Muir

Abstract

<p><b>Background and Purpose:</b> European directives and legislation in some countries forbid inclusion of subjects incapable of consent in research if recruitment of patients capable of consent will yield similar results. We compared brain lesion volumes in stroke patients deemed to have capacity to consent with those defined as incapacitated.</p>\ud \ud <p><b>Methods:</b> Data were obtained from 3 trials recruiting patients primarily with cortical stroke syndromes. Patients were recruited within 24 hours of onset and used MRI based selection or outcome criteria. Method of recruitment was recorded with stroke severity, age, and brain lesion volumes on Diffusion Weighted Imaging.</p>\ud \ud <p><b>Results:</b> Of the 56 subjects included, 38 (68%) were recruited by assent and 18 (32%) by consent. The assent group had a median lesion volume of 18.35 cubic centimetres (cc) (interquartile range [IQR] 8.27–110.31 cc), compared to 2.79 cc (IQR 1.31–12.33 cc) when patients consented (P=0.0004). Lesions were smaller than 5 cc in 7/38 (18%) in the assent group and 11/18 (61%) in the consent group (P=0.0024). There was good correlation between neurological deficit by NIH stroke scale score and lesion volume (r=0.584, P<0.0001). Logistic regression demonstrated NIHSS or lesion volume predicted capacity to consent.</p>\ud \ud <p><b>Conclusions:</b> Patients with acute stroke who retain capacity to consent have significantly smaller infarct volumes than those incapable of consent, and these are frequently below the limits where measurement error significantly compromises valid use of volumetric end points. Only a small proportion of patients with capacity to consent would be eligible for, and contribute usefully to, most acute stroke trial protocols.</p&gt

Publisher: American Heart Association
Year: 2008
OAI identifier: oai:eprints.gla.ac.uk:17845
Provided by: Enlighten

Suggested articles

Citations

  1. (2000). Adults with incapacity (Scotland) Act 2000–excerpt. Bull Med Ethics.
  2. Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. doi
  3. Classification and natural history of clinically identifiable subtypes of cerebral infarction. doi
  4. DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. doi
  5. (2001). Directive 2001/20/EC of the European Parliament and of the Council of 4 doi
  6. EPITHET Investigators. Refining the perfusion-diffusion mismatch hypothesis. doi
  7. (2005). Ethical issues of informed consent in acute stroke. Analysis of the modalities of consent in 56 patients enrolled in urgent therapeutic trials. Cerebrovasc Dis. doi
  8. (2008). Informed consent in trials for neurological emergencies: the example of subarachnoid haemorrhage.
  9. IST-3 Collaborative Group. Impact of stroke syndrome and stroke severity on the process of consent in the Third International Stroke Trial. Cerebrovasc Dis. doi
  10. (2006). Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. doi
  11. (2012). Measurements of acute cerebral infarction: a clinical examination scale. doi
  12. (2001). New imaging strategies for patient selection for thrombolytic and neuroprotective therapies. doi
  13. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. doi
  14. (1995). Subjective experiences of 24 patients dramatically recovering from stroke. doi
  15. (2005). The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.